United States · FDA National Drug Code directory
emtricitabine, rilpivirine and tenofovir disoproxil fumarate
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 42385-801_7193c90e-456c-4cfb-8181-65a1618dae51
- Product NDC
- 42385-801
- Form
- TABLET, FILM COATED
- Composition / generic term
- emtricitabine, rilpivirine and tenofovir disoproxil fumarate
- Labeler
- Laurus Labs Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20260305
- Source listing expiry
- 20271231
Source-listed ingredients
- EMTRICITABINE — 200 mg/1
- RILPIVIRINE HYDROCHLORIDE — 25 mg/1
- TENOFOVIR DISOPROXIL FUMARATE — 300 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET, FILM COATED in 1 BOTTLE (42385-801-30) · 42385-801-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →